Ahammune Biosciences Secures $5 Million in Series A Funding
Pune-based biotech startup Ahammune Biosciences has successfully raised $5 million in a Series A funding round, led by pi Ventures. The funding round also saw participation from a range of other prominent investors, including Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing investors Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.
This latest funding infusion brings the total amount raised by Ahammune Biosciences to around $8 million, with the company having previously secured $3 million from its existing investors and other sources. The fresh funds will be used to propel the company’s R&D efforts, with a focus on conducting Phase II human clinical trials for its drug candidates, expanding its patent portfolio, and advancing its work on other immune-mediated skin diseases.
Co-founded in 2016 by Parul Ganju and Krishnamurthy Natarajan, Ahammune Biosciences is a clinical-stage therapeutics company that aims to create innovative solutions to treat and cure skin diseases. With a focus on chronic skin conditions, the company leverages its proprietary small molecule therapeutics platform to target and enhance skin health. Ahammune’s mission is to deliver cost-effective, innovative treatments that address unmet needs in dermatology, paving the way for a brighter future in skin disease therapies.
Ahammune’s initial program is centered on developing a new drug candidate for vitiligo, a condition characterized by the loss of skin pigmentation. According to the company, its small molecule drug candidate has a unique mechanism of action that stimulates the function of color-producing cells in the skin, induces repigmentation, and does not cause generalized immunosuppression. In addition to vitiligo, Ahammune is developing a pipeline of patented molecules to treat other dermatological and autoimmune diseases.
The company is committed to expanding its patent portfolio around its proprietary technology โ the small molecule therapeutics platform โ and is seeking partnerships with pharmaceutical companies to co-develop its assets and maximize their commercial potential.
